Exacerbations of chronic obstructive pulmonary disease (COPD) 
INTRODUCTION
Chronic obstructive pulmonary disease (COPD) is an inflammatory lung disease comprising small airways disease and emphysema [1] . It is currently the 6 th most common cause of death globally and is predicted to become the 3 rd most common cause of death by 2020 [2] . This may be due to the increased incidence of cigarette smoking as this is the most common risk factor for COPD and contributes to approximately 85% of all cases.
Approximately, 15% of smokers will develop COPD whereas the incidence in non-smokers is 1.6% [3] . In healthy individuals and smokers without lung obstruction, the lower airways are sterile, but in COPD patients there is often colonization of the lower respiratory tract, with Streptococcus pneumoniae and
Haemophilus influenzae being the most common bacterial pathogens [4] .
Exacerbations of COPD are an increasing cause of hospitalizations in the UK [5] , are associated with accelerated disease progression [6] and account for much of the healthcare costs associated with COPD [7, 8] . The causes of exacerbations vary, but ~50% of infective exacerbations are bacterial in origin.
Alveolar macrophages contribute 90-95% of cells found in bronchoalveolar lavage fluid and are highly phagocytic, producing multiple inflammatory mediators [9] . Moreover, their role in removal of potentially pathogenic microorganisms via phagocytosis is essential in maintaining the normally sterile environment within the lung. One reason for the increased incidence of bacterial infections in the respiratory tract of COPD patients might be failure of macrophages to clear pathogens because of reduced phagocytosis due to chronic activation [10, 11] .
Alveolar macrophages from COPD patients phagocytose fewer apoptotic epithelial cells [12] and Escherichia coli [13] compared with nonsmokers and less H. influenzae compared with smokers without COPD [14] .
Presently, there are no animal models of this aspect of COPD limiting study to primary human cells. Therefore, we compared the phagocytic responses of alveolar macrophages and monocyte-derived macrophages (MDM) from COPD patients with cells from non-smokers and smokers without lung obstruction. The use of MDM examined whether reduced phagocytic responses of alveolar macrophages in COPD was due to these cells becoming replete or whether differentiation in a specific, pro-inflammatory, lung environment was required to establish this defect.
METHODS

Subject selection
Healthy subjects and smokers were recruited from the NHLI, Royal Brompton Demographic data are presented in Table 1 . COPD patients were significantly older than the control groups but there were no differences in smoking history with the smoking controls ( Table 1) .
Cell culture
Monocytes were isolated from PBMC using a Monocyte Isolation kit II (Miltenyi Biotec, Surrey, UK) and cultured in the presence of 2ng/ml GM-CSF for 12d to generate MDM as described previously [15] . Alveolar macrophages were isolated from BAL fluid as described previously [16] .
Phagocytosis assays
Non-typeable H. influenzae strain 1479 and S. pneumoniae serotype 9V, strain 10692 were cultured and heat killed at 60ºC for 2h. Bacteria were fluorescently labelled using Alexafluor 488 dye (2mg/ml in DMSO) in the dark, Grids were transferred to the TEM for visualization. 
Confocal microscopy
Statistical Analysis
Data are presented as mean ± SEM for 'n' observations. Comparisons between subject groups or cell types were performed using Kruskal-Wallis analysis using GraphPad Prism software followed by Dunn's multiple comparison test (GraphPad Software Inc., San Diego, CA) or a Mann-Whitney test where appropriate. Differences were considered significant where p<0.05.
RESULTS
Comparison of alveolar macrophage and MDM phagocytosis
Initial experiments demonstrated that phagocytosis of polystyrene beads by both alveolar macrophages and MDM were similar (Fig. 1a) .
Moreover, MDM from non-smokers, smokers and COPD patients phagocytosed beads equally (Fig. 1b) which was confirmed as internalization by confocal microscopy (Fig. 1c) . This would indicate that the MDM model reflects alveolar macrophage phagocytosis and that inert particle removal is not altered in COPD. In order to ascertain whether similar responses were observed when macrophages were exposed to bacteria, a series of experiments were devised. Alveolar macrophages from COPD patients phagocytosed less E. coli compared with cells from non-smokers and smokers (Fig. 2a) . By contrast, monocytes from each of the subject groups had low phagocytic responses that did not differ with either smoking or disease status (Fig. 2b) . However, MDM from COPD patients exhibited a reduced capacity to ingest bacteria similar to that of alveolar macrophages (Fig.2c) . We confirmed this observation using FACS analysis. Phagocytosis by MDM from non-smokers and smokers were similar (Figs. 2d and e) but cells from COPD patients exhibited a significant curve shift to the left (Fig. 2f ),
indicating that fewer cells had engulfed bacteria. These comparative phagocytosis experiments suggest that in COPD, defective macrophage phagocytosis is acquired during differentiation and that MDM may be useful for studying the underlying defective mechanism.
MDM phagocytosis of H.influenzae and S.pneumoniae
To investigate whether this reduced phagocytic response to bacteria was restricted to E.coli the phagocytic responses of MDM to fluorescentlylabelled H. influenzae, S. pneumoniae and E. coli were evaluated. All MDM phagocytosed the three bacterial strains in a concentration-dependent manner (Fig. 3a-c) but the response of COPD MDM was attenuated, not only towards E. coli (Fig 3a) but also for S. pneumoniae (Fig. 3b) Despite COPD patients having smoked more cigarettes than smokers and being older (see Table 1 ) there were no correlations between either age or number of cigarettes smoked (pack-years) and phagocytosis of any bacteria examined.
Cell surface expression of receptors involved in bacterial recognition
There are numerous receptors involved in bacterial recognition by macrophages [17, 18] thus reduced receptor expression in COPD could account for attenuated phagocytosis. However, there were no differences in the expression of TLR2, CD14, TLR4, or CD163 on MDM from COPD patients compared with cells from the other subject groups (Table 2 ). There were also no differences in expression of non-specific scavenger receptors including the mannose receptor, macrophage receptor with collagenous structure (MARCO) or CD36 (Table 2) . Nor were there any differences in expression of the phosphatidylserine (PS) receptor or HLA-DR on these cells (Table 2) .
MDM from COPD patients phagocytosed beads normally (Fig. 1b) limiting defective phagocytosis to engulfment of pathogenic bacteria. Since there were no differences in expression of a number of receptors considered important in recognition of non-opsonized particles (Table 2) , the downstream mechanisms emanating from receptor ligation that regulate phagocytic responses were examined. Pharmacological modulation of these pathways was utlilized to investigate whether altered signal transduction could account for these observations. The phosphoinositol-3-kinase (PI3K) inhibitor, LY-294002 and the p38 inhbitior, SB 203580, inhibited MDM phagocytosis of E.
coli from all subjects similarly (Figs. S1a and S1c). By contrast, the Rho kinase inhibitor, Y-27632, had no effect on phagocytosis at any of the concentrations tested (Fig. S1b) .
Effect of pharmacological agents on MDM phagocytosis
COPD patients are currently taking a variety of medicaments to ameliorate their symptoms. These include glucocorticosteroids and bronchodilators. Therefore, it was possible that systemic effects of these drugs could alter the responses of blood-derived macrophages. To test this possibility, MDM from non-smokers, smokers and patients with COPD were pre-treated with various pharmacological agents prior to phagocytosis assay (Fig. 5) .
Exposure of MDM to budesonide improved the phagocytic responses of cells from COPD patients and smokers towards both H.influenzae and S.pneumoniae (Figs. 5a and 5d ). Agents that elevate cAMP are considered to be inhibitory for phagocytosis [19] , however formoterol did not inhibit phagocytosis of the bacteria in this system (Figs. 5b and 5e) but stimulated the response of cells from smokers. There was no effect on the responses of cells derived from patients with COPD. The macrolide, azithromycin, is reported to restore the phagocytic response of alveolar macrophages from COPD patients and enable removal of apoptotic cells [20] , however in this system azithromycin had no effect on the response of cells from patients with COPD but improved the responses of cells from smokers (Figs. 5c and 5f).
Other drugs (tiotropium bromide (10 prescribed commonly to patients with COPD had no effect on the phagocytic response (data not shown). showed reduced phagocytosis of this bacterium between cells from smokers and COPD patients. This discrepancy might reflect sensitivity of labelling between commercially obtained phagocytic prey and bacteria labelled 'inhouse'. Another study has suggested previously that alveolar macrophages from COPD patients phagocytose less H. influenzae compared with cells from smokers but not non-smokers [14] . In contrast to our data, they reported no differences in responses of COPD MDM [14] . The reason for this discrepancy with our data is unclear but may reflect differences in the methods used to differentiate monocytes to MDM. Our methodology employed the use of GM-CSF which drives monocytes towards a more alveolar macrophage-like phenotype [23] and we also further validated our model by comparison with alveolar macrophages with respect to phagocytosis of polystyrene beads and
DISCUSSION
Examination of the mechanism of reduced bacterial clearance by COPD macrophages led to investigation of cell surface molecules that could be responsible for recognition of bacteria leading to phagocytosis. However, these analyses indicated that various receptors were expressed similarly on MDM from all subject groups. This contrasts to reports that have shown that TLR2 is decreased on the surface of alveolar macrophages in smokers and patients with COPD [24] . Although, TLR may modulate the phagocytic response [25] , the observation that removal of both Gram positive and Gram negative bacteria is reduced in COPD would suggest that these receptors are not pivotal in this response. Furthermore, the concept that reduced alveolar macrophage phagocytosis in COPD is due to cells becoming replete in the lung environment is unlikely as MDM, differentiated in vitro show the same reduced response.
Investigation into the cell signalling pathways showed that phagocytosis was mediated by a PI-3-kinase dependent mechanism but that Rho kinase is unlikely to be involved. Rho kinase is critical in complement receptor-mediated but not FcR-mediated phagocytosis [26] and is inhibitory during phagocytosis of apoptotic cells [27] . As Y-27632 had no effect on phagocytosis of E. coli by MDM, the defective mechanism in COPD cells is likely to be distinct from that of apoptotic cells and complement opsonised particles. The inhibition of the phagocytic response by a non-selective PI-3-kinase inhibitor and a p38 inhibitor could limit the benefit of these agents as putative anti-inflammatory therapies in diseases such as COPD where the phagocytic response in already suppressed.
Since this study utilised circulating cells that were subsequently differentiated, systemic levels of pharmacological agents used for the treatment of COPD may be responsible for the suppression of the phagocytic response observed in this study. However, none of the pharmaceutical agents examined suppressed phagocytosis of either H. influenzae or S.pneumoniae in cells from any of subject groups. Therefore, it is unlikely that differences in treatment regimes between the COPD patients and the control groups could account for the suppressed phagocytic response. It is of note that budesonide stimulated the phagocytic response in MDM obtained from patients with COPD. Although glucocorticosteroids do not improve the long term decline in lung function observed in COPD patients, they have been shown to reduce exacerbation frequency [28] . This may be due to improved phagocytic responses of macrophages in the lungs of these patients. However, the concentrations of steroid required to significantly improve phagocytosis in vitro are high (10 -7 -10 -6 M) and unlike alveolar macrophages from COPD patients, MDM do respond to steroids (data not shown).
In summary, MDM from COPD patients demonstrate reduced phagocytosis for common airway pathogens. This defect is specific to pathogenic bacteria. MDM from COPD patients are not replete, nor has differentiation occurred in a chronically inflamed lung, suggesting that lack of pathogen removal is an inherent defect in circulating monocytes from COPD patients that unmasks during maturation into macrophages. This defect in phagocytosis of bacteria that most frequently cause acute exacerbations of COPD is likely to be an important factor leading to colonization of the lower airways and the propensity for bacterial exacerbations. Furthermore, the persistence of bacteria in the lower airways may act as a chronic antigenic drive for pulmonary inflammation and could contribute to the increased numbers of T-and B-lymphocytes in the airways of COPD patients [29] .
Defining the molecular basis of this defect may lead to identification of susceptibility markers for airway obstruction in asymptomatic smokers and to development of novel therapies that stimulate phagocytic functions, leading to sterilisation of the respiratory tract and a reduction in the bacterial load that may drive chronic inflammation in COPD patients. 
